The updated version(2019) of the NCCN guidelines for ovarian cancer has changed the recommendations for stage 1A OCCC treatment to "observe" as an option. For many years, the need as well as the efficacy of chemo (carboplatin/taxol) has been questioned for this group of patients not only by international researchers, but in the U.S. as well. They appear to have only added one new study in the references for the 2019 NCCN version with regards to this specific situation. I had very strong reservations about subjecting my body to chemo, yet it was strongly recommended by two of the most reputable institutions treating cancer so I did follow this course. I'm now really concerned about the long term consequences of having had this treatment when it probably wasn't necessary (secondary cancer). I never understood why the NCCN included treatment of ovarian clear cell carcinoma with all of the other types of ovarian cancer as it is not the same disease. At this point, I am wondering why it took this much time to change the recommendation with all of the evidence that existed and to ask for reassurance that I did not allow for irreparable harm to my body by subjecting it to these toxic chemicals.